Seres Therapeutics Inc

MCRB

Get informed when a big investor buys or sells

Market Cap$46.77M

Close$

Compare to Similar Companies

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
Seres Therapeutics Inc	-0.9	-	-177%	-	3

$12.00

Target Price by Analysts

139.8% upsideSeres Therapeutics Target Price Details

$-3.56

Current Fair Value

171.2% downside

Overvalued by 171.2% based on the discounted cash flow analysis.

Share Statistics

Market cap	$46.77 Million
Enterprise Value	$97.44 Million
Dividend Yield	$- (-)
Earnings per Share	$0.64
Beta	0.1
Outstanding Shares	9,582,533

Return

Return on Equity	-176.98%
Return on Assets	-39.87%
Return on Invested Capital	-84.86%

Valuation & Multiples

P/E Ratio	-0.93
PEG	0.58
Price to Sales	-
Price to Book Ratio	2.5
Enterprise Value to Revenue	84.95
Enterprise Value to EBIT	-1.17
Enterprise Value to Net Income	-3
Total Debt to Enterprise	0.83
Debt to Equity	3.04

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date

August 5, 2026

EPS Estimate

$-2.18

Average shareholder expectation

Revenue Estimate

$179,000

Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio	2.1940▲ 146.23%
Total Calls	56,700▼ 67.34%
Total Puts	124,400▼ 2.07%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %	24.07%▼ 3.81%
Total Invested	$20.46M▼ 43.75%
Investors Holding	36▼ 4.00%

ESG Score